Tu1939 Performance Testing of IBDoc®, a Novel Smartphone-Based Monitoring System for Measuring Fecal Calprotectin: Comparison to ELISA &amp; Rapid Test

Shaw, Collin; Spies, Peter; Ueberschlag, Marie-Eve; Prica, M; Kräuchi, S; Reinhard, Christian; Weber, Jakob

doi:10.1016/s0016-5085(16)33332-7

Gastroenterology

2016

DOI: 10.1016/s0016-5085(16)33332-7

|View full text |Cite

Tu1939 Performance Testing of IBDoc®, a Novel Smartphone-Based Monitoring System for Measuring Fecal Calprotectin: Comparison to ELISA & Rapid Test

Collin Shaw¹,

Peter Spies²,

Marie-Eve Ueberschlag³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Fecal biomarkers in inflammatory bowel disease: how, when and why?

Ministro

Martins

2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

Over the last thirty years knowledge on fecal biomarkers (FM) has substantially increased. Nowadays these non-invasive inflammation markers are used in the daily management of inflammatory bowel disease (IBD). The interest in investigating FM was motivated by the need of a simple, quick, disposable and less invasive marker of disease activity, which might remove the need for endoscopy when following up with patients. Areas covered: Current literature was reviewed for articles regarding the role of FM in IBD diagnosis, activity, flare prediction, medication and surgical treatment response as well as how FM may differ in adult and paediatric IBD patient populations. Expert commentary: Although FM is relevant in IBD patient follow-up, there isn't enough data regarding FM reference values for different ages, different disease subtypes, disease localization/extension or response to therapy. Serial measurements of FM for each patient may be useful in accessing relapse in most patients. FM presented more consistent results when used as a predictive tool of relapse after ileocecal surgery in Crohn's disease. Ongoing research will clarify FM role in decision-making IBD daily practice.

show abstract

Fecal biomarkers in inflammatory bowel disease: how, when and why?

Ministro

Martins

2017

Expert Review of Gastroenterology & Hepatology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Tu1939 Performance Testing of IBDoc®, a Novel Smartphone-Based Monitoring System for Measuring Fecal Calprotectin: Comparison to ELISA & Rapid Test

Cited by 1 publication

References 0 publications

Fecal biomarkers in inflammatory bowel disease: how, when and why?

Fecal biomarkers in inflammatory bowel disease: how, when and why?

Contact Info

Product

Resources

About